Welcome to our dedicated page for Trinity Biotech news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech stock.
Trinity Biotech plc reports developments across its commercial-stage diagnostics and health technology business, including clinical laboratory products, point-of-care testing, diabetes management solutions, and wearable biosensor development. Its updates frequently cover the Premier Hb9210 HbA1c laboratory blood glucose monitoring platform, TrinScreen HIV testing, and the CGM+ continuous glucose monitoring program.
Company news also addresses specialty diagnostics initiatives such as EpiCapture prostate cancer testing and autoimmune biomarker work supported by its New York State Department of Health-certified reference laboratory. Other recurring topics include commercial operations in North America, manufacturing and cost-control actions under its Comprehensive Transformation Plan, ADS-based financing arrangements, trading updates, and Nasdaq listing-status notices.
Trinity Biotech (Nasdaq: TRIB) will report its financial results for Q1 FY2022 on June 30, 2022.
The company has scheduled a conference call at 11:00 AM ET on the same day to discuss these results. Interested parties can join by dialing in or via a webcast link provided in the release.
This call is crucial for stakeholders seeking insights into the company's performance amid ongoing challenges in the diagnostic market.
Trinity Biotech (Nasdaq: TRIB) has secured a CE Mark for its rapid Covid-19 antigen test, allowing its use across the European Union and other CE-recognizing countries. The test boasts a quick 10-minute result time, 99% sensitivity, and 99% specificity, providing a reliable alternative to current testing methods. Unlike traditional nasopharyngeal swabs, this test uses a less invasive anterior nasal swab, enhancing patient comfort. Manufactured in Bray, Ireland, the company aims to expand its testing portfolio while exploring regulatory approvals in other regions.
Trinity Biotech (Nasdaq: TRIB) announced the successful closing of a $45 million strategic investment from MiCo Ltd on May 3, 2022. This investment includes approximately 11.2 million ADSs priced at $2.25 each and a $20 million unsecured junior convertible note with a 1.5% interest rate. The funds will primarily be used to repay part of the company's $81.25 million term loan, potentially saving $4 million annually in interest. The investment aims to enhance Trinity Biotech's capital structure and facilitate growth opportunities in the diagnostics industry.
Trinity Biotech (TRIB) reported fiscal year 2021 revenues of $93.0 million, down 8.8% from $102.0 million in 2020. Point-of-Care revenues rose by 12.2% to $10.3 million, driven by HIV sales in Africa. Clinical Laboratory revenues fell 10.9% to $82.6 million, primarily due to a decline in PCR Viral Transport Media sales. Gross margins decreased to 41.0% from 47.6%. Operating profit before one-off items decreased to $13.8 million, with profit after tax at $0.9 million, contrasting with a loss of $6.4 million in 2020. Q4 2021 saw revenues drop 40.4% year-over-year to $19.5 million.
Dublin-based Trinity Biotech (TRIB) announced a strategic $45 million investment from MiCo Ltd, a KOSDAQ-listed biomedical company. This investment includes 11.2 million ADSs priced at $2.25 each, representing a 130% premium. MiCo will hold 29.9% of TRIB's voting shares. Additionally, a seven-year unsecured convertible note of $20 million at 1.5% interest will be issued. Funds will primarily reduce TRIB's $81.25 million loan, cutting annual interest costs by $4 million. The partnership aims to enhance TRIB's point-of-care diagnostics and leverage MiCo’s technology for growth.
Trinity Biotech (TRIB) has received WHO approval for its new HIV screening product, TrinScreen™ HIV. This rapid test yields results in under 12 minutes and targets a significantly larger market than its predecessor, with an estimated size exceeding USD 150 million. The company, known for its Uni-Gold™ HIV confirmatory test in Africa, anticipates strong sales growth due to enhanced brand reputation and an experienced marketing team. TrinScreen™ HIV will be produced at their Bray, Ireland facility, and there are potential opportunities in emerging markets globally.
Trinity Biotech (Nasdaq: TRIB) has successfully completed its refinancing, closing a $81.25 million senior secured term loan with Perceptive Advisors. This loan will help retire approximately $99.7 million of exchangeable senior notes issued by its subsidiary. The CEO expressed enthusiasm for partnering with Perceptive Advisors to advance the company's growth. Trinity Biotech specializes in developing diagnostic systems for point-of-care and clinical laboratory markets, with a global presence in over 75 countries.
Trinity Biotech plc (Nasdaq: TRIB) announced the results of its Extraordinary General Meeting (EGM) held on January 25, 2022. Shareholders approved four resolutions necessary for the refinancing of approximately $99.9 million in exchangeable senior notes. Approval included a new term loan, increasing authorized share capital, and granting the board authority to issue shares without limit under Irish law. Notably, each resolution received at least 97% of the votes in favor, indicating strong shareholder support for these refinancing measures.
Trinity Biotech plc (TRIB) reported Q3 2021 revenues of $22.0 million, a decrease of 31.3% from $32.0 million in Q3 2020, largely due to a 40.3% drop in Clinical Laboratory revenues. Point-of-Care revenues rose by 99.2% to $4.1 million, driven by increased HIV testing in Africa. The company entered into an $81.25 million loan facility to refinance existing debt, with plans to retire $99.7 million in outstanding senior notes. Gross profit was $8.9 million, resulting in a margin of 40.4%. The company anticipates a positive future with innovative products and improved capital structure.
Trinity Biotech (Nasdaq: TRIB) reported Q2 2021 revenues of $25.8 million, up 61.3% from $16.0 million in Q2 2020. Point-of-Care revenue grew by 54.5% to $2.0 million, driven by increased HIV sales in Africa. Clinical Laboratory revenue surged 61.9% to $23.9 million, primarily due to COVID-19 related products. Gross profit was $11.0 million with a margin of 42.7%. Operating profit reached $6.3 million, markedly up from $0.5 million in the same period last year. The company anticipates regulatory approval for its new TrinScreen™ HIV test and aims to launch a COVID-19 rapid antigen test by Q2 2022.